1877.HK Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 Jun 2024 @ 10:08):
Our systems believe the stock currently is overvalued by -0.03% compare to its pairs and should correct downwards.

Stats
Tagesvolumen	635 742
Durchschnittsvolumen	1.14M
Marktkapitalisierung	26.72B
EPS	HKD-0.290 ( Q1 \| 2024-03-31 )
Nächstes Ertragsdatum	( HKD0 ) 2024-08-27
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-5.29 (Sector) 14.27 (Industry) 6.31
ATR14	HKD0.0250 (0.21%)

0690.HK 0.00%

1061.HK -0.82%

1167.HK 3.31%

1177.HK -1.11%

1228.HK 0.00%

1477.HK 1.63%

1521.HK -2.44%

1530.HK 2.71%

1548.HK -1.42%

1672.HK -3.61%

1873.HK 0.00%

1875.HK -0.45%

1877.HK -0.51%

1952.HK -2.59%

2096.HK -0.69%

2126.HK -2.00%

2137.HK -0.98%

2142.HK 1.47%

2157.HK -3.80%

2162.HK -2.88%

2171.HK -2.04%

2179.HK -3.00%

2197.HK -1.45%

2256.HK -0.61%

2257.HK 0.00%

2616.HK 2.70%

2696.HK -0.65%

3759.HK -1.63%

6160.HK 1.17%

6600.HK 0.86%

6622.HK 0.71%

6628.HK 1.33%

6821.HK -0.10%

6826.HK 1.76%

6978.HK 23.00%

6996.HK 0.00%

6998.HK 0.00%

9688.HK -0.15%

9926.HK -2.33%

9939.HK -4.59%

9966.HK -0.41%

9969.HK 3.66%

9995.HK -4.67%

Korrelation (AI algo v.1.1b): Overvalued: -0.03% HKD11.70 paired level. (Der Algorithmus verfolgt in Echtzeit die Änderungen der am stärksten korrelierten Aktien und gibt eine sofortige Aktualisierung)

Volumen Korrelation

Lang: 0.06 (neutral)

Kurz: -0.02 (neutral)

Signal:(55.264) Neutral

JUNSHI BIO Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

JUNSHI BIO Korrelation - Währung/Rohstoff

0.08
( neutral )

-0.21
( neutral )

0.00
( neutral )

0.27
( neutral )

0.24
( neutral )

-0.29
( neutral )

JUNSHI BIO Finanzdaten

Annual	2023
Umsatz:	HKD1.50B
Bruttogewinn:	HKD835.26M (55.59 %)
EPS:	HKD-2.32

FY	2023
Umsatz:	HKD1.50B
Bruttogewinn:	HKD835.26M (55.59 %)
EPS:	HKD-2.32

FY	2022
Umsatz:	HKD1.45B
Bruttogewinn:	HKD927.21M (63.79 %)
EPS:	HKD-2.81

FY	2021
Umsatz:	HKD4.02B
Bruttogewinn:	HKD2.77B (68.74 %)
EPS:	HKD-0.800

Financial Reports:

No articles found.

JUNSHI BIO Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

JUNSHI BIO

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.